Amazon.com Inc. (AMZN) was reiterated a ‘Hold’ by Canaccord Genuity analysts on Monday. The broker also raised its price target on the stock to $400 from $380 saying it sees constructive signals in AWS growth, profitability, and potential valuation. Amazon’s AWS segment is expected to generate $15+ billion in revs by fiscal 2018 and expand operating margin to around 22% by then.
Amazon.com Inc. shares have a PEG and forward P/E ratio of 32.10 and 165.05, respectively. Price/Sales for the same period is 2.18 while EPS is ($0.88). Currently there are 22 analysts that rate AMZN a ‘Buy’, 16 rate it a ‘Hold’. No analyst rates it a ‘Sell’. AMZN has a median Wall Street price target of $470.00 with a high target of $600.00.
In the past 52 weeks, shares of e-commerce giant have traded between a low of $284.00 and a high of $452.65 and are now at $423.99. Shares are up 31.91% year-over-year and 38.53% year-to-date.
bluebird bio, Inc. (BLUE) was reiterated as ‘Overweight’ with a $244 from $200 price target on Monday by JP Morgan (JPM).
BLUE shares recently lost $0.76 to $180.05. In the past 52 weeks, shares of Cambridge, Massachusetts-based company have traded between a low of $29.73 and a high of $197.35. Shares are up 615.51% year-over-year and 97.13% year-to-date.
Sunesis Pharmaceuticals, Inc. (SNSS) rating of ‘Buy’ was reiterated today at ROTH Capital with a price target increase of $5.50 from $4 (versus a $2.62 previous close).
SNSS shares recently gained $0.12 to $2.74. ROTH’s target price suggests a potential upside of about 101% from the company’s current stock price.
Over the past year, shares of South San Francisco, Calif.-based firm have traded between a low of $1.00 and a high of $8.46. Shares are down 56.11% year-over-year ; up 2.75% year-to-date.
Shares of RedHill Biopharma Ltd. (RDHL) are up $2.50 to $18.96 in mid-day trading after ROTH Capital reiterated its ‘Buy’ rating and increased its 12-month base case estimate on the name by 2.5 points to $30 a share.
RedHill Biopharma, currently valued at $177.74 miilliion, has a median Wall Street price target of $26.75 with a high target of $30.00. Approximately 1.13 million shares have already changed hands, compared to the stock’s average daily volume of 30K.
Shares of Bio Blast Pharma Ltd. (ORPN) are up $1.53 at $7.29, after ROTH Capital this morning raised its price target on the shares to $25 from $18, and reiterated a ‘Buy’ rating.
Bio Blast shares have declined 3.36% in the last 4 weeks and 11.52% in the past three months. Over the past 5 trading sessions the stock has lost 1.03%. Shares of Bio Blast Pharma Ltd. are down 9.86% this year.